Effects of classical and atypical antipsychotics on dopamine receptor binding of 123I-epidepride, cognition, startle response and extrapyramidal side-effects in drug-naive first-episode schizophrenic patients.

Trial Profile

Effects of classical and atypical antipsychotics on dopamine receptor binding of 123I-epidepride, cognition, startle response and extrapyramidal side-effects in drug-naive first-episode schizophrenic patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2011

At a glance

  • Drugs Risperidone; Zuclopenthixol
  • Indications Schizophrenia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 16 Sep 2011 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
    • 16 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top